Oric Pharmaceuticals
Presença
Oric Pharmaceuticals é uma das ...
Oric Pharmaceuticals é uma empresa listada sob o símbolo ORIC (US).
Fusão, aquisição e financiamento envolvendo Oric Pharmaceuticals.
- Oric Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 85 milhões de dólares. (publicado em 28 de junho de 2023).
Executivos
Veja o organograma con seus 13 executivos principais
Biografias mais buscadas da Oric Pharmaceuticals
- Jacob Chacko, Chief Executive Officer and Director
- Mardi Dier, Director
- Richard Heyman, Chairman of the Board
Criar um alerta
para seguir os movimentos de executivos da Oric Pharmaceuticals.
Farmacêutica
Oric Pharmaceuticals possui 1.868 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
- Frontier Medicines acaba de anunciar uma arrecadação de fundos de 80 milhões de dólares. (publicado em 27 de fevereiro de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Oric Pharmaceuticals
- ORIC Pharmaceuticals to Present at the Jefferies Healthcare Conference | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals Announces Presentation of Preclinical Data on Glucocorticoid Receptor Antagonist Overcoming Resistance to an Androgen Receptor Degrader at the 32nd EORTC-NCI-AACR Symposium 2020 | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Update | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at the 2020 American Association for Cancer Research Virtual Annual Meeting II | ORIC Pharmaceuticals, Inc.
- View more press releases Close
Redes sociais sobre Oric Pharmaceuticals
- Oric Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Oric Pharmaceuticals na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Jacob Chacko 
Ligue para a Oric Pharmaceuticals em +1 650...
